R M Conti

Summary

Affiliation: University of Chicago
Country: USA

Publications

  1. ncbi request reprint Infused chemotherapy use in the elderly after patent expiration
    Rena M Conti
    The University of Chicago, IL 60637, USA
    Am J Manag Care 18:e173-8. 2012
  2. doi request reprint National trends in spending on and use of oral oncologics, first quarter 2006 through third quarter 2011
    Rena M Conti
    Rena M Conti is an assistant professor of health policy and economics in the Departments of Pediatrics and Health Studies at the University of Chicago, in Illinois
    Health Aff (Millwood) 33:1721-7. 2014
  3. doi request reprint The 340B drug discount program: hospitals generate profits by expanding to reach more affluent communities
    Rena M Conti
    Rena M Conti is an assistant professor of health policy and economics in the Departments of Pediatrics and Health Studies at the University of Chicago, in Illinois
    Health Aff (Millwood) 33:1786-92. 2014
  4. doi request reprint The impact of emerging safety and effectiveness evidence on the use of physician-administered drugs: the case of bevacizumab for breast cancer
    Rena M Conti
    Department of Pediatrics, Section of Hematology Oncology, The University of Chicago, Chicago, IL 60637, USA
    Med Care 51:622-7. 2013
  5. pmc Prevalence of off-label use and spending in 2010 among patent-protected chemotherapies in a population-based cohort of medical oncologists
    Rena M Conti
    Department of Pediatrics, Section of Hematology Oncology, University of Chicago, Chicago, IL, USA
    J Clin Oncol 31:1134-9. 2013
  6. doi request reprint Nonprofit biomedical companies
    R M Conti
    Department of Pediatrics, Section of Pediatric Hematology Oncology, Center on Health and the Social Sciences, Program on Pharmaceutical Policy, Cancer Research Center, The University of Chicago, Chicago, Illinois, USA
    Clin Pharmacol Ther 84:194-7. 2008
  7. doi request reprint Overuse of antidepressants in a nationally representative adult patient population in 2005
    Rena Conti
    Department of Pediatrics and the Center for Health and the Social Sciences, University of Chicago, 5481 S Maryland Ave, Chicago, IL 60610, USA
    Psychiatr Serv 62:720-6. 2011

Detail Information

Publications7

  1. ncbi request reprint Infused chemotherapy use in the elderly after patent expiration
    Rena M Conti
    The University of Chicago, IL 60637, USA
    Am J Manag Care 18:e173-8. 2012
    ..The use of anticancer drugs (chemotherapies) is an important determinant of national spending trends. Recent policies have aimed to accelerate generic entry among chemotherapies to generate cost savings...
  2. doi request reprint National trends in spending on and use of oral oncologics, first quarter 2006 through third quarter 2011
    Rena M Conti
    Rena M Conti is an assistant professor of health policy and economics in the Departments of Pediatrics and Health Studies at the University of Chicago, in Illinois
    Health Aff (Millwood) 33:1721-7. 2014
    ..Spending on new and patent-protected oral oncologics and associated price increases are significant drivers of increased spending...
  3. doi request reprint The 340B drug discount program: hospitals generate profits by expanding to reach more affluent communities
    Rena M Conti
    Rena M Conti is an assistant professor of health policy and economics in the Departments of Pediatrics and Health Studies at the University of Chicago, in Illinois
    Health Aff (Millwood) 33:1786-92. 2014
    ..Our findings support the criticism that the 340B program is being converted from one that serves vulnerable patient populations to one that enriches hospitals and their affiliated clinics. ..
  4. doi request reprint The impact of emerging safety and effectiveness evidence on the use of physician-administered drugs: the case of bevacizumab for breast cancer
    Rena M Conti
    Department of Pediatrics, Section of Hematology Oncology, The University of Chicago, Chicago, IL 60637, USA
    Med Care 51:622-7. 2013
    ..Although these drugs may be targets of future policy efforts to rationalize use, little is known regarding how physicians respond to emerging safety and effectiveness evidence...
  5. pmc Prevalence of off-label use and spending in 2010 among patent-protected chemotherapies in a population-based cohort of medical oncologists
    Rena M Conti
    Department of Pediatrics, Section of Hematology Oncology, University of Chicago, Chicago, IL, USA
    J Clin Oncol 31:1134-9. 2013
    ..The prevalence of off-label anticancer drug use is not well characterized. The extent of off-label use is a policy concern because the clinical benefits of such use to patients may not outweigh costs or adverse health outcomes...
  6. doi request reprint Nonprofit biomedical companies
    R M Conti
    Department of Pediatrics, Section of Pediatric Hematology Oncology, Center on Health and the Social Sciences, Program on Pharmaceutical Policy, Cancer Research Center, The University of Chicago, Chicago, Illinois, USA
    Clin Pharmacol Ther 84:194-7. 2008
    ..We conclude with a suggestion that opportunities exist for nonprofit firms focused on cancer diagnostics, given the limitations of current financing incentives and ripe scientific opportunity...
  7. doi request reprint Overuse of antidepressants in a nationally representative adult patient population in 2005
    Rena Conti
    Department of Pediatrics and the Center for Health and the Social Sciences, University of Chicago, 5481 S Maryland Ave, Chicago, IL 60610, USA
    Psychiatr Serv 62:720-6. 2011
    ..This study aimed to provide an estimate of antidepressant overuse in a more recent, nationally representative sample of adults and with a more contemporary set of antidepressants than has been covered in prior studies...